Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunological Targeting of Pathological Tau Proteins

a technology of pathological tau and immunological targeting, which is applied in the field of immunological targeting of pathological tau proteins, can solve the problems of complex cognitive assessment and sensory motor abnormalities, and achieve the effects of promoting the clearance of aggregates, slowing the progression of tau-pathology related behavioral phenotypes, and high target specificity

Inactive Publication Date: 2014-10-09
NEW YORK UNIV
View PDF3 Cites 27 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a new treatment for Alzheimer's disease and other tau-related neurodegenerative diseases. It involves using specific peptides and antibodies that mimic narrow phospho-epitopes of pathological tau, which are important targets for preventing and treating these diseases. The immunotherapy approaches described herein have high target specificity and minimal risk of producing an adverse immune response towards the normal tau protein. This approach can help generate a robust immune response against pathological tau with minimal risk of producing an adverse immune response towards the normal tau protein.

Problems solved by technology

One of these models, the P301L mouse model (Lewis et al., “Neurofibrillary Tangles, Amyotrophy and Progressive Motor Disturbance in Mice Expressing Mutant (P301L) Tau Protein,”Nat. Genet. 25:402-405 (2000)), recapitulates many of the features of frontotemporal dementia although the CNS distribution of the tau aggregates results primarily in sensorimotor abnormalities which complicates cognitive assessment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunological Targeting of Pathological Tau Proteins
  • Immunological Targeting of Pathological Tau Proteins
  • Immunological Targeting of Pathological Tau Proteins

Examples

Experimental program
Comparison scheme
Effect test

example 1

Peptides

[0103]The peptide immunogens were synthesized at the Keck facility (Yale University), by the solid-phase technique on a p-methyl-benzhydrylamine resin, using a Biosearch SAM 2 synthesizer (Biosearch, Inc., San Rafael, Ca.). The peptides were cleaved from the resin with HF and then extracted with ether and acetic acid before lyophilization. Subsequently, the peptides were purified by HPLC with the use of a reverse-phase support medium (Delta-Bondapak) on a 0.78×30 cm column with a 0-66% linear gradient of acetonitrile in 0.1% TFA.

example 2

Animals Used in Studies

[0104]Studies were performed in the transgenic (Tg) JNPL3 P301L mouse model that develops neurofibrillary tangles in several brain regions and spinal cord (Taconic, Germantown, N.Y.) (Lewis et al., “Neurofibrillary Tangles, Amyotrophy and Progressive Motor Disturbance in Mice Expressing Mutant (P301L) Tau Protein,”Nat Genet. 25:402-405 (2000), which is hereby incorporated by reference in its entirety). While this model is not ideal for AD, it is an excellent model to study the consequences of tangle development and for screening therapy that may prevent the generation of these aggregates. Another advantage of these animals is the relatively early onset of pathology. In the homozygous line, behavioral abnormalities associated with tau pathology can be observed at least as early as 3 months, but the animals remain relatively healthy at least until 8 months of age. In other words, at 8 months, the animals ambulate, feed themselves, and can perform the behavioral ...

example 3

Vaccine Administration

[0107]Phos-tau peptides were mixed with Adju-Phos adjuvant (Brenntag Biosector, Denmark) at a concentration of 1 mg / ml and the solution was rotated overnight at 4° C. prior to administration to allow the peptide to adsorb onto the aluminum phosphate particles.

[0108]JNPL3 P301L mice received a subcutaneous injection of 100 μl followed by a second injection 2 weeks later and then monthly thereafter (unless otherwise indicated). Vaccination started at 2-3 months of age and continued until the animals were 8-9 months of age at which time the animals were perfused and their organs collected for analysis. The mice went through a battery of sensorimotor tests at 5-6 months and again at 8-9 months of age prior to sacrifice. Control mice received the adjuvant alone.

[0109]htau / PS1 / mtau− / − mice (n=12) were immunized with the phosphorylated tau immunogen Tau379-408[P-Ser396,404]. Three non-immunized control groups were included that received adjuvant alone. The main contro...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.

Description

[0001]This application claims priority to U.S. Non-Provisional patent application Ser. No. 12 / 813,297, filed Jun. 10, 2010 (pending) and U.S. Provisional Patent Application Ser. No. 61 / 185,895, filed Jun. 10, 2009 (expired), each of which applications is hereby incorporated by reference in its entirety.[0002]The subject matter of this application was made with support from the United States Government under the National Institutes of Health, Grant No. AG032611. The U.S. Government has certain rights.FIELD OF THE INVENTION[0003]The present invention is directed to immunological methods and compositions for preventing, treating, and diagnosing Alzheimer's disease and related tauopathies, and inhibiting the accumulation of tau neurofibrillary tangles and / or their pathological tau precursors in a subject.BACKGROUND OF THE INVENTION[0004]An emerging treatment for Alzheimer's disease (AD) is immunotherapy to clear amyloid-β (Aβ). Another important target in AD and frontotemporal dementia ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395C07K16/18
CPCA61K39/3955A61K2039/507C07K16/18A61K39/0005A61K39/0007A61K39/39A61K39/395C07K14/4711G01N33/6896G01N2800/2821A61K2039/505C07K2317/76C07K2317/20A61P21/00A61P21/02A61P21/04A61P25/00A61P25/14A61P25/16A61P25/28A61P37/04A61P43/00Y02A50/30
Inventor SIGURDSSON, EINAR M.
Owner NEW YORK UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com